PRESIDENTProf. Pierre Marquet
Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in
physiology in 1992. After several years as an assistant professor at Limoges University Hospital, he became an associate professor of
pharmacology in 1998 and since 2001, has been a full professor at the Faculty of Medicine of Limoges, France. He was presented with the
Young Scientist Award of the French Society of Analytical Toxicology in 1995, the IATDMCT Young Investigator Award in 2001 and C.E.
Pippenger Award in 2009. At the IATDMCT, he chaired the Standard of Laboratory Practice Committee from 2001-2007, was elected Secretary
in 2007 and then President-elect in 2009.
Pierre Marquet is currently:
- Director of the INSERM U850 research unit called “Pharmacology of immunosuppressive drugs in transplantation” (INSERM is the French Institute of Medical and Health Research)
- Head of the “Pharmacology, Toxicology and Pharmacovigilance” Department at the University Hospital of Limoges
- Vice-President of the board of Directors of University Hospital of Limoges, in charge of research
- Member of the council of the French Society of Pharmacology and Therapeutics (SFPT)
- Coordinator of the “drugs and pharmacology” working group of the French-speaking Society of Transplantation (SFT)
- Member of several scientific committees
Pierre Marquet conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ
transplantation, which covers: new analytical methodologies for IS; metabolic, pharmacogenetic and pharmacodynamic studies of the IS;
investigation of early biomarkers; epidemiological studies and clinical trials in transplant patients; and application to routine
treatment personalization in transplant recipients.
He has published over 160 papers in peer-reviewed, international journals.
Dr. Pierre Marquet
Pharmacology & Toxicology
University Hospital Limoges
2 av Martin Luther King
Limoges Cedex 87042
Dr. Pierre Wallemacq
Dr. Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches
clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of
the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD
theses and post-doc fellows. He is also head of laboratory in the Cliniques universitaires St Luc, Brussels, in charge of the analytical
biochemistry platform regrouping activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry (GC, HPLC,
UPLC, LC-MSMS, GC-MS). He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author
of more than 150 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 170 conferences on invitation. Most
of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry of TDM/TOX areas. Pierre
Wallemacq is the current president of the Royal Belgian Society of Clinical Chemistry (SBCC-BVKC), and of the Belgian and Luxemburg
society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring
(TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for
Clinical Biochemistry. Recently, he has been elected President-Elect of the International Association of Therapeutic Drug Monitoring and
Clinical Toxicology (IATDMCT).
Head of Laboratory
Dept. of Clinical Chemistry
University Hospital St. Luc
Av. Hippocrate 10
B-1200 Bruxelles 1200
Dr. Alexander Vinks
Alexander (Sander) Vinks is
Professor of Pediatrics and Pharmacology (Adj.) at the University of Cincinnati, Colleges of Medicine and Pharmacy. He is the director of
the Division of Clinical Pharmacology, principal investigator of the NIH Pediatric Pharmacology Research Unit at Cincinnati
Children’s and Director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management. Dr. Vinks received his
pharmacy and pharmacology training at Leiden University and the University of Toronto, Canada. He received specialty training in clinical
pharmacy (PharmD) and clinical pharmacology (PhD) at The Hague Hospitals Central Pharmacy and Leiden University in the Netherlands. Dr.
Vinks is board certified in Clinical Pharmacology and Toxicology. Before joining the Division of Clinical Pharmacology at Cincinnati
Children’s in 2000, he was Director of the centralized Clinical Pharmacology & Toxicology Laboratory for the city of The Hague.
His major research interests include pharmacokinetic-pharmacodynamic (PK/PD) modeling, pharmacogenetics (PG) and the application of
genomic, population and simulation approaches (Pharmacometrics) to clinical trial design, Therapeutic Drug Monitoring (TDM) and
individualized Bayesian dosing strategies. His current research includes the development of biomarker assays for the measurement of
pharmacodynamic effects of immunosuppressive drugs. Dr. Vinks has ongoing NIH funding to further advance PK/PD/PG modeling and simulation
in pediatric patients with a focus in optimizing immunosuppressive and antimicrobial therapies. He is directing several clinical
pharmacology cores for ongoing multi-center clinical studies evaluating target controlled therapies using population model-based
approaches. Dr. Vinks has received several distinctions for his research, including the Huizinga Award for Research in Hospital Pharmacy
from the Netherlands. Dr. Vinks is president-elect of the International Association of Therapeutic Drug Monitoring and Clinical
Toxicology. He is chairing the Therapeutic Monitoring and Toxicology (THE) scientific section of the American Society of Clinical
Pharmacology and Therapeutics (ASCPT) and is a fellow of the American College of Clinical Pharmacology. He is on the Editorial Board of
Antimicrobial Agents and Chemotherapy, Clinical Therapeutics, Therapeutic Drug Monitoring, Journal of Pediatric Pharmacology and
Therapeutics, and the Journal of Clinical Medicine (Bulgaria). Dr. Vinks is an internationally renowned speaker with more than 140
presentations at national and international meetings. He has authored over 70 peer-reviewed publications and 14 book chapters and reviews
in the areas of PK/PD modeling, pharmacogenetics and TDM.
Alexander A. Vinks
Professor and Division Director
Division of Clinical Pharmacology
Cincinnati Children’s Hospital and Medical Center
MLC 6018, Oak South Room 2529
3333 Burnet Avenue
Cincinnati OH 45229-3039
Dr. Donald LeGatt
Dr. LeGatt is a Clinical Biochemist who has been head of the Clinical Toxicology and Therapeutic Drug
Monitoring Laboratory at University of Alberta Hospital, Edmonton for thirty years. He is a Clinical Professor at the University of
Alberta with teaching responsibilities in the Faculty of Medicine and Dentistry and has been a Consultant Toxicologist at
DynaLIFE, Edmonton for thirteen years. His actual “roots” are in Pharmacy, having obtained both his Bachelor’s
and Ph.D degrees in the discipline. He has been a Member of IATDMCT since 1990, and has previously served as a Councilor and Director of
Education. He has also served on the organizing Committees of three Congresses. This is his second consecutive 2y term as IATDMCT
Secretary. Dr. LeGatt is a Founding Fellow of the Canadian Academy of Clinical Biochemistry (CACB), and has been a member of the Canadian
Society of Clinical Chemists (CSCC) and the American Association of Clinical Chemistry (AACC) since 1983. He has also served three terms
as President of the Alberta Society for Human Toxicology (ASHT). He has received several awards: a Capital Health “Esprit de Corps”
Recognition Award in 1997; a CSCC International Visitor Award in 2001; in 2005, the Certificate for Meritorius Service from the College
of Physicians and Surgeons of Alberta, the CSCC Education Excellence Award and a Capital Health Reach Award for Innovation Excellence;
“Outstanding Speaker Award” from AACC in 2006 and 2009; in 2008, a City of Spruce Grove Award of Excellence for Innovation and a CSCC
Best Poster Award; in 2009, the “Teacher of the Year Award” in Clinical Pathology, University of Alberta. He is an avid proponent of
progressive, rational clinical toxicology testing. Dr. LeGatt’s research interests span the areas of toxicokinetics, applied
pharmacokinetics and method development. He has over 100 publications, abstracts and book articles to his credit.
Department of Laboratory Medicine & Pathology
University of Alberta Hospital
Edmonton, AB T6G 2B7
Dr. Loralie Langman
Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of
Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry
training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British
Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is
currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory
Med/Pathology, Mayo Clinic College of Medicine.
Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, and Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.
Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation Of Clinical Chemistry And Laboratory Medicine (IFCC) and The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).
She has over 35 peer reviewed publications, 7 book chapters, and over 45 abstracts/presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.
Loralie J. Langman
Toxicology and Drug Monitoring Laboratory
200 First Street SW
Rochester MN 55905
DIRECTORS OF EDUCATION
Mr. Paul Taylor
Paul Taylor graduated with a BSc in Applied Chemistry from the Queensland University of Technology in 1986. Since 1987, he
has worked in the Department of Clinical Pharmacology at the Princess Alexandra Hospital in Brisbane, Australia. He currently holds the
position of Senior Scientist, Clinical Mass Spectrometry Facility within the Department of Clinical Pharmacology. The focus of his
research is on the application of HPLC-MS/MS to the clinical setting. Paul’s current research has centred on the improved patient
outcomes through individualisation of immunosuppressant and anticancer drugs, improved diagnosis of primary aldosteronism and the
detection of the iron biomarker, hepcidin.
Paul has authored or co-authored over 80 peer reviewed papers and 120 abstracts. He is an editorial board member of Therapeutic Drug Monitoring and was recently appointed an Editor of Journal of Chromatography B. Paul has been an active member of The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) since 1997. He was previously elected a Councilor on the Board of IATDMCT (2003-2007). In 2003, Paul received the IATDMCT Young Investigator Award.
Department of Clinical Pharmacology
Princess Alexandra Hospital
3rd Floor – R Wing, Building One
Ipswich Road, Woolloongabba
Brisbane, Qld 4102
Dr. Teun Van Gelder
Dr. Teun van Gelder is an internist and clinical pharmacologist in the Department of Hospital Pharmacy at the Erasmus
Medical Center in Rotterdam, the Netherlands. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and
completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-
doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University, and was
awarded the Young Investigator Award from the American Society for Transplantation for his work during this time. Dr. van Gelder’s
current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring.
Teun Van Gelder
Erasmus Medical Center
Rotterdam 3015 GD
Dr. Eberhard Wieland
Eberhard Wieland is Professor of Clinical Chemistry and Laboratory Medicine . He is Medical Director and head of the Central Institute
for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany.
Dr. Wieland received his MD in Biochemistry from the Ruprecht-Karls-University, Heidelberg in 1982. The topic of his thesis was on the hepatotropic mushroom toxin phalloidin. From 1983 to 1984 he was resident in Internal Medicine at the University Hospital, Heidelberg. From 1984-1985 he received his training in Medical Microbiology at the same university.
In 1985 he was awarded a research fellowship by the Volkswagen foundation which he spent between 1985 and 1987 at the Department of Endocrinology and Metabolism of the University of California, San Diego, USA.
From 1987 to 1993 he received his training in Clinical Chemistry and Laboratory Medicine at the Georg-August-University Goettingen. In 1993 he was certified in Clinical Chemistry and became consultant in Laboratory Medicine. Since 2005 he is registered European Clinical Chemist.
From 1996 to 2003 Dr. Wieland served as senior physician at the Department of Clinical Chemistry, Georg-August-University, Goettingen. After his Habilitation 1997 he was appointed Professor of Clinical Chemistry in 2000.
Dr. Wieland became Medical Director and head of the Central Institute of Clinical Chemistry and Laboratory Medicine of Klinikum Stuttgart in 2003. He is s adjunct professor of Clinical Chemistry and Laboratory Medicine with teaching responsibilities at the Medical Faculty of the Eberhard-Karls-University in Tuebingen. A focus of his consulting and teaching activities is therapeutic drug monitoring and clinical toxicology.
Dr. Wieland conducts research in pharmacokinetics and pharamacodynamics of immunosupressant drugs. His current research interest is in biomarkers to complement TDM. In addition, he performs funded research on oxidative stress in transplantation medicine and atherosclerosis for many years.
Dr. Wieland has contributed over 80 articles to peer reviewed scientific journals and 16 book chapters on the topics TDM, atherosclerosis, oxidative stress, and biomarkers. He has presented more than 160 lectures and posters at national and international events. He is editorial board member of Clinical Biochemistry, Canada, Folia Medica Plovid, Bulgaria, and Journal of Laboratory Medicine, Germany. He is also an active referee for German accreditation bodies.
Central Institute of Clinical Chemistry and Laboratory Medicine
Dr. Olof Beck
Dr. Olof Beck studied chemistry at the Royal Institute of Technology in Stockholm and received his Ph.D. degree in 1982 after working
at the Karolinska Institute with studies on biogenic amines using gas chromatography-mass spectrometry methods. After a post-doctoral
period at Stanford University and two years in pharmaceutical industry he returned to Karolinska Institute and department of Clinical
Pharmacology in 1988. Dr. Beck is at present adjunct professor and laboratory director of the Pharmacology Laboratory comprising TDM,
genotyping, clinical and workplace drugs-of-abuse testing, sports doping control and contract analyses in clinical trials. He has been
active assessor in laboratory accreditation in the Nordic countries.
Research activities have resulted in about 200 publications. Areas of interest are method developments in pharmacology and toxicology with special focus on mass spectrometry, alcohol biomarkers and toxicology. Most recent work is focussed on Internet drugs, breath testing for abused drugs and alcohol biomarker phosphatidylethanol.
Dept. of Clinical Pharmacology
Dr. Frank T. Peters (Germany)
Frank T. Peters was born in Trier, Germany, in 1971, where he also went to elementary school and
high school. He started studying pharmacy at the Johann-Wolfgang-Goethe University in Frankfurt/Main, Germany, in 1993 and obtained the
licence to practice as a pharmacist in 1998.
Thereafter, he started working as a research assistant and PhD student of Prof. Dr. Dr. h.c. Hans H. Maurer at the Department of Experimental and Clinical Toxicology of the Saarland University in Homburg, Germany, where he finished his PhD thesis in June of 2003. From then to the end of 2008 he worked in the same department as a post-doc and deputy of Prof. Maurer. In June 2009 he finished his habilitation (licence to lecture at the university) in the field of pharmacology and toxicology at the Medical Faculty of the Saarland University. Since 2009 he is the Head of Forensic and Clinical Toxicology at the Institute of Forensic Medicine at the University Hospital in Jena, Germany.
The main research interests of Frank T. Peters are biotechnological synthesis of drug metabolites, enantioselective analysis of amphetamines and amphetamine-like designer drugs, analysis of new designer drugs in blood samples, metabolism of drugs and poisons, determination of sedating drugs in the context of declaration of brain death, and experimental designs and statistical procedures for analytical method validation.
Frank T. Peters is author or co-author of 59 peer-reviewed publications, one book and six book chapters. He is a member of The International Association of Forensic Toxicologists (TIAFT), the German Pharmaceutical Society (DPhG), the Society of Toxicological and Forensic Chemistry (GTFCh), and of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT). Frank T. Peters is chairman of IATDMCT’s and TIAFT’s Young Scientist Committees.
During the TIAFT meeting in Melbourne in 2003 he received the TIAFT Young Scientist Award for Best Paper Published in 2002 for his publication on “Bioanalytical method validation and its implications for forensic and clinical toxicology – A review.” In 2007, he received the Young Scientist Award of the GTFCh. The IATDMCT Young Investigator Award was presented to him during the IATDMCT meeting in Montreal, 2009.
Frank T. Peters
Head of Toxicology
Insitute of Forensic Medicine
Friedrich Schiller University of Jena
Jena Thueringen D-07743
Prof. Dr. Katharina M. Rentsch
Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist’s license in 1988.
Thereafter she was trained at the Institute for Clinical Chemistry in the University Hospital Zurich, Switzerland and got a certification
as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on
therapeutic drug monitoring of cytostatic drugs at the ETH Zurich. In 2003 Katharina M. Rentsch finished her habilitation in the field of
clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical
faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich.
In 2007 she certified as a clinical toxicologist GTFCh.
Since 1994 Katharina M. Rentsch is the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry in the University Hospital Zurich and since 2004 she is also the deputy head of the institute. Starting in December 2011 she will become the head of the division of clinical chemistry at the University Hospital Basel, Switzerland.
The main research interest of Katharina M. Rentsch is the development of new analytical methodologies for therapeutic drug monitoring and clinical toxicology and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of > 90 peer-reviewed publications, 8 book chapters and > 50 published oral or poster presentations.
Katharina M. Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organisations. Since 2006 she is member of the Clinical Toxicology/Drugs of Abuse Committee of the IATDMCT and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.
University Hospital Basel
Dr. Benedetta Salustio (Australia)
Dr Sallustio was awarded her PhD in 1990 from Flinders University in South Australia. She is currently Principal Medical
Scientist in the Department of Clinical Pharmacology at The Queen Elizabeth Hospital, and Affiliate Associate Professor in the Discipline
of Pharmacology at the University of Adelaide, in South Australia.
Dr Sallustio’s area of research interests include drug metabolism and transport, particularly understanding how inter-individual differences in these processes, either genetic or environmental, impact on drug toxicity and clinical efficacy. She has pursued three main arms of research: i) the role of metabolism in enhancing drug toxicity, particularly intracellular protein and genetic damage; ii) applying an understanding of metabolic pathways and their genetic variability to enhance the clinical use of the anti-anginal agent perhexiline; and iii) applying an understanding of variability in the metabolism and cellular transport of immunosuppressants to improving clinical outcomes in renal transplant recipients. This work has been supported by major competitive funding from the National Heart Foundation, the Anti Cancer Foundation, the National Health and Medical Research Council, and the Juvenile Diabetes Research Foundation, and has resulted in 63 peer-reviewed publications in international journals and 107 presentations at national and international scientific meetings.
Dr Sallustio is a member of a number of national and international scientific societies and currently serves as Convenor of the Adelaide Pharmacology Group, is on the Scientific Advisory Committee of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (since 2007), the Special Drugs Working Party of the Australasian Association of Clinical Biochemists (since 2011), and is an elected Councillor of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (since 2009).
Benedetta C. Sallustio
Principal Medical Scientist
The Queen Elizabeth Hospital
Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011